Trials / Unknown
UnknownNCT05737368
Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 11 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness in the treatment of recurrent glioblastoma with Cadonilimab combined with fractionated radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | fractionated radiotherapy | fractionated radiotherapy (500cGy \*5F, 600cGy\*5F, 350cGy\*10F, according to the tumor volume) |
| DRUG | cadonilimab | Cardunizumab (10mg/kg, Q3W, d1) |
Timeline
- Start date
- 2023-02-28
- Primary completion
- 2024-02-28
- Completion
- 2025-02-28
- First posted
- 2023-02-21
- Last updated
- 2023-02-21
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT05737368. Inclusion in this directory is not an endorsement.